On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: Double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 89-99

  Saletu, B ^a   Grunberger J ^a   Anderer, P ^a   Linzmayer, L ^a   Konig P ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Landesnervenkrankenhaus Valduna ^*  (Austria)

Author keywords

Antiglutamatergic drug; Attention variability; Brain protection; Calcium channel blocker; Caroverine; EEG mapping; Fine motor activity; Hypoxia; Hypoxic hypoxidosis; Memory; Psychometry

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAROVERINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; BLOOD GAS ANALYSIS; BRAIN PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOXIA; MALE; MEMORY; MOTOR ACTIVITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOLUNTEER;

ADULT; ANOXIA; BRAIN; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHOMETRICS; QUINOXALINES; REFERENCE VALUES;

EID: 0030057533     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00165.x     Document Type: Article

References (50)

1. Amaducci L, Angst J, Bech P, et al. Consensus conference on the methodology of clinical trials of 'Nootropics', Munich, June 1989. Pharmacopsychiatry 1990; 23: 171-175.
2. Saletu B, Grünberger J. Cerebral hypoxic hypoxidosis: Neurophysiological, psychometric and pharmacotherapeutic aspects. In Adv biol Psychiat, Basel: Karger, 1983: 146-164.
3. Saletu B, Grünberger J, Anderer P. Proof of antihypoxidotic properties of tenilsetam in man by EEG and psychometric analyses under an experimental hypoxic hypoxidosis. Drug Dev Res 1987; 10: 135-155.
4. Saletu B, Anderer P, Grunberger J. EEG brain mapping in gerontopsychopharmacology: On protective properties of pyritinol against hypoxic hypoxidosis. Psychiatry Res 1989; 29, No. 3: 387-390.
5. Saletu B, Grünberger J, Linzmayer L, Anderer P. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm Park Dis Dement Sect 1990; 2: 305-325.
6. Saletu B, Grünberger J, Anderer P. On brain protection of codergocrine mesylate (Hydergine®) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 510-524.
7. Saletu B, Grunberger J, Linzmayer L, Anderer P. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry. Psychopharmacology 1992; 109: 30-40.
8. Saletu B, Schulz H, Herrmann WM, Anderer P, Shrotriya RC, Vanbrabant E. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Pharmacopsychiatry 1994; 27: 189-197.
9. Hornykiewicz O, Hitzenberger G, Zellner H. Experimentell-pharmakologische und klinische Untersuchungen über ein neues Spamsolytikum 'Spadon' (Prüfbez.P. 201-1). Wien Klin Wochenschr 1963; 11: 189-197.
10. Kudo Y, Shibata S. Effects of caroveine and diltiazem on synaptic responses, L-glutamate-induced depolarization and potassium efflux in the frog spinal cord. Br J Pharmacol 1984; 83: 813-820.
11. Möslinger D. Ein Beitrag zur Prüfung der Wirksamkeit und Verträglichkeit eines neuen Spasmolytikums. Subsidia Medica 1970; 22(3): 1-4.
12. Profanter M. Erfahrungen mit hochdosiertem Caroverin bei zerebralen Durchblutungsstörungen. Therapiewoche Österreich 1987; 2(9): 926-935.
13. Koppi S, Eberhardt G, Haller R, König P. Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal - caroverine versus meprobamate in a randomized double-blind study. Neuropsychobiology 1987; 17: 49-52.
14. Ehrenberger K, Felix D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug induced neuroprotection? Neuropharmacology 1992; 31: 1259-1263.
15. Ehrenberger K, Felix D. Receptor pharmacological models for inner ear therapies with emphasis on glutamate receptors: a survey. Acta Otolaryngol 1995; 115: 236-240.
16. Frandsen A, Drejer J, Schousboe A. Direct evidence that excitotoxicity in cultured neurons is mediated via N-methyl-D-aspartate (NMDA) as well as non-NMDA receptors. J Neurochem 1989; 53: 297-299.
17. Dubinsky JM, Rothman SM. Intracellular calcium concentrations during 'chemical hypoxia' and excitotoxic neuronal injury. J Neurosci 1991; 11: 2545-2551.
18. Drian MJ, Kamenka JM, Pirat JL, Privat A. Noncompetitive antagonists of N-methyl-D-aspartate prevent spontaneous neuronal death in primary cultures of embryonic rat cortex. J Neurosci Res 1991; 29: 133-138.
19. Mosinger JL, Price MT, Bai HY, et al. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neurol 1991; 113: 10-17.
20. Lipton SA. Models of neuronal injury in AIDS: another role for the NMDA receptor? Trends Neurosci 1992; 15: 75-79.
21. Kohmura E, Yamada K, Hayakawa T, Kinoshita A. Neurotoxicity caused by glutamate after subcritical hypoxia is prevented by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX): an in vitro study using rat hippocampal neurons. Neurosci Lett 1991; 121: 159-162.
22. Patel JB, Zinkand WC, Thompson C, Keith R, Salama AI. Role of glycine in the N-methyl-D-aspartate-mediated neuronal cytotoxicity. J Neurochem 1990; 54: 849-854.
23. Patel JB, Ross LE, Duncan B, et al. Administration of glycine antagonists, HA-966 and 7-chlorokynurenic acid reduce ischemic brain damage in gerbils. Soc Neurosci Abstr 1989; 15: 43.
24. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honoré T. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990; 247: 571-574.
25. Saletu B, Grünberger J, Anderer P, Linzmayer L, König P. On the acute, central effects of caroverine-a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneim Forsch Drug Res 1995; 45: 217-229.
26. Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992; 45: 79-93.
27. Grünberger J. Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Wien: Maudrich, 1977.
28. Grünberger J, Linzmayer L. Computergesteuerte klinischpsychodiagnostische Methoden in der Psychiatrie. Neuropsychiatrie 1991; 4: 89-98.
29. Von Zerssen D, Koeller DM, Rey ER. Die Befindlichkeitsskala (B-S) - ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneim Forsch Drug Res 1970; 20: 915-918.
30. Abt K. Descriptive data analysis (DDA) in quantitative EEG studies. In Statistics and topography in quantitative EEG, eds Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P. Amsterdam: Elsevier, 1988: 150-160.
31. Duffy FH, Bartels PH, Burchfield JL. Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 1981; 51: 455-462.
32. Saletu B, Anderer P, Kinsperger K, Grünberger J. Topographic brain mapping of EEG in neuropsychopharmacology - part II. Clinical applications (Pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 1987; 9(6): 385-408.
33. Hamer J, Wiedemann K, Berlet H, Weinhardt F, Hoyer S. Cerebral glucose and energy metabolism, cerebral oxygen consumption and blood flow in arterial hypoxaemia. Acta Neurochir 1978; 44: 151-160.
34. Hoyer S. Chronic cerebrovascular disease and brain metabolism at rest clinical application to drug studies in middle-aged and elderly patients. In Drugs and methods in CVD, ed SIR. New York-Oxford-Toronto-Sydney-Frankfurt-Paris: Pergamon Press, 1981: 131-137.
35. Strughold H. Hypoxidose. Klin Wochenschr 1944; 23: 221-222.
36. Cahn J. Influence of aging on the cerebral response to experimental hypoxia and edema. In Drugs and methods in CVD, ed SIR. New York-Oxford-Toronto-Sydney-Frankfurt-Paris: Pergamon Press, 1980: 153-162.
37. Takahashi T. Activation methods. In Electroencephalography, eds Niedermayer E, Lopes de Silva F. Munich: Urban & Schwarzenberg, 1982: 179-195.
38. Saletu B, Hitzenberger G, Grünberger J, et al. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with two new formulations of piracetam (infusion and syrup) under hypoxia in man. Int J Clin Pharmacol Ther Toxicol 1995; 33: 249-262.
39. Head H. The conception of nervous and mental energy. II. Vigilance: a physiological state of the nervous system. Br J Psychol 1923; 14: 125-147.
40. Bente D. Vigilanz: Psychophysiologische Aspekte. Verh Dtsch Ges Inn Med 1977; 83: 945-952.
41. Saletu B, Anderer P, Paulus E, et al. EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Disord 1991; 5, Suppl. 1: 57-75.
42. Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry 1992; 32: 668-681.
43. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995; 117: 385-395.
44. Kornmüller AE, Palme F, Strughold H. Die Ableitung der Gehirnaktionsströme, eine Methode zur Untersuchung der Höhenkrankheit. Klin Wochenschr 1942; 21: 5-8.
45. Gurvich AM, Ginsburg DA. Types of hypoxic and posthypoxic delta activity in animals and man. Electroencephalogr Clin Neurophysiol 1977; 42: 297-308.
46. Maier-Lenz H, Ringwelski L, Klein G, Richter W. Zur Frage der Wirksamkeitsprüfung von zerebralaktiven Arzneimitteln. Vorläufige Mitteilung über ein Modell zur Erprobung zerebralaktiver Arzneimittel an Probanden. Arzneimittelforschung 1980; 30: 830-832.
47. Schaffler K. Pharmakodynamische Bioäquivalenz von Piracetam unter hypoxischer Hypoxie. Arzneimittelforschung 1986; 26: 845-849.
48. Saletu B, Grünberger J, Anderer P, Linzmayer L. Effect of the novel antiglutamate, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. Meth Find Exp Clin Pharmacol 1995; in press.
49. Saletu B. Neurophysiological aspects of aging and gerontopsychopharmacology. In Diagnosis and Treatment of Old Age Dementias, eds Ban TA, Lehmann HE. Basel: Karger, 1989; 43-55.
50. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-622.